Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Kyowa Hakko Kirin Co Ltd    4151   JP3256000005

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2017 348 B
EBIT 2017 -
Net income 2017 22 354 M
Finance 2017 23 142 M
Yield 2017 1,16%
Sales 2018 346 B
EBIT 2018 -
Net income 2018 24 099 M
Finance 2018 36 356 M
Yield 2018 1,23%
P/E ratio 2017 50,04
P/E ratio 2018 45,39
EV / Sales2017 3,51x
EV / Sales2018 3,50x
Capitalization 1 245 B
More Financials
Company
Kyowa Hakko Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products.It operates through the Pharmaceuticals and Bio-Chemicals segments.The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and... 
More about the company
Surperformance© ratings of Kyowa Hakko Kirin Co Ltd
Trading Rating : Investor Rating :
More Ratings
Latest news on KYOWA HAKKO KIRIN CO LTD
11:13a Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion ..
12/13 KYOWA HAKKO KIRIN : Announces Results of Phase 3 Clinical Study of Mogamulizumab..
12/12 KYOWA HAKKO KIRIN : Announces Results of Phase 3 Clinical Study of Mogamulizumab..
12/11 KYOWA HAKKO KIRIN : Poteligeo meets in Phase III for CTCL
12/08 REATA PHARMACEUTICALS, INC. (NASDAQ : RETA) Files An 8-K Entry into a Material D..
12/07 KYOWA HAKKO KIRIN : Announces FDA Acceptance for Filing and Priority Review Desi..
12/05 Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 ..
12/05 Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 ..
12/04 KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data fr..
12/01 KYOWA HAKKO KIRIN : Submits the Partial Change Approval Application of Mogamuliz..
More news
Sector news : Specialty & Advanced Pharmaceuticals
11:38a PROCTER & GAMBLE : P&G appoints Peltz to board despite losing proxy battle
11:38a NELSON PELTZ : P&G appoints Peltz to board despite losing proxy battle
12/15 JAZZ PHARMACEUTICALS : Pennsylvania man admits to trading on tips about drug com..
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
11/29 YOUR DAILY PHARMA SCOOP : Omeros If And Buts, Egalet's Oxycodone Success, Auris ..
11/28 Ardelyx and Kyowa Hakko Kirin inks deal for Tenapanor for Cardiorenal disease..
11/28 FDA grants priority review status to Kyowa Hakko Kirin's BLA for Mogamulizuma..
04/10 3 THINGS IN BIOTECH YOU SHOULD LEARN : Volume 4
01/05 Ultragenyx and Kyowa Kirin announce MAA for KRN23 filed and accepted for revi..
Chart KYOWA HAKKO KIRIN CO LTD
Duration : Period :
Kyowa Hakko Kirin Co Ltd Technical Analysis Chart | 4151 | JP3256000005 | 4-Traders
Technical analysis trends KYOWA HAKKO KIRIN CO LTD
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 360  JPY
Spread / Average Target 9,3%
EPS Revisions
Managers
NameTitle
Nobuo Hanai President & Representative Director
Yoichi Sato Director, Managing Executive Officer, GM-R&D
Kazuyoshi Tachibana Director & Managing Executive Officer
Toshifumi Mikayama Director & Managing Executive Officer
Masashi Miyamoto Director & Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA HAKKO KIRIN CO LTD33.44%11 050
ABBVIE53.78%155 345
MERCK KGAA-9.18%13 747
JAZZ PHARMACEUTICALS PLC24.28%8 125
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD38.39%5 638
CONVATEC GROUP-13.13%5 395